Omega Diagnostics Group, the Scotland based in-vitro diagnostics company, announced that it has entered into an exclusive, worldwide licensing agreement with Immunodiagnostic Systems Holdings Plc (IDH) to develop and market allergy diagnostic tests using IDH's IDS-iSYS automated platform. Omega originally announced its intention to enter into this agreement in November 2010 when it acquired the allergy in-vitro diagnostics (IVD) business of Germany based Allergopharma.

Omega intends to develop high speed, automated allergy tests for the clinical laboratory market and compete with Phadia AB, the current market leader. Omega plans to leverage the IDS-iSYS system, which has underpinned strong growth at IDH over the last year in the specialist immunoassay market, to offer a more modern, efficient and flexible system than is currently in the market.

Omega also announced that the Allergopharma business has performed according to expectations over the first two months since the acquisition, with like for like sales rising 7% during the period. 

Unlock the rest of this article with a 14 day trial

Unlock with Email
Unlock with Google

Already have an account?
Login here